News
ONCO
3.030
-19.41%
-0.730
Onconetix, Inc. Stockholders Approve Reverse Stock Split Authority and Issuance of Up to 154,856,150 Shares
NASDAQ · 6h ago
Onconetix Stockholders Approve All Matters at Annual Meeting
TipRanks · 13h ago
Onconetix, Inc. Effects 1:10 Reverse Stock Split
NASDAQ · 3d ago
Realbotix Extends Merger Completion Date With Onconetix To March 31, 2027
Benzinga · 3d ago
Onconetix Inc trading resumes
TipRanks · 3d ago
Onconetix Inc trading halted, volatility trading pause
TipRanks · 3d ago
Onconetix Completes One-for-Ten Reverse Stock Split Adjustment
TipRanks · 3d ago
Weekly Report: what happened at ONCO last week (1102-1106)?
Weekly Report · 3d ago
Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
Healthcare Stocks Advance: OBX Surges 38%, ONCO Gains 32%, TMDX Rises 26%
NASDAQ · 6d ago
Onconetix, Inc. Amends Share Exchange Agreement with Realbotix, Extending End Date to March 31, 2027
NASDAQ · 6d ago
Onconetix Amends Realbotix Share Exchange Agreement, Extends End Date
TipRanks · 6d ago
Onconetix Enters Amendment To Share Exchange Agreement Regarding Merger With Realbotix; If The Net Cash Is Less Than $12.5M And Parties Proceed With Closing, The Seller Will Own 95% Of The Buyer's Shares
Benzinga · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 11/03 21:05
Weekly Report: what happened at ONCO last week (1026-1030)?
Weekly Report · 11/02 10:06
Stock Splits on Deck This Week (November 2 to November 6) – Stay Invested
TipRanks · 11/01 15:24
Onconetix Announces Realbotix Rolls Out Humanoid Robot Platform Echo
Benzinga · 10/27 12:32
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/27 12:05
Onconetix Plans 1-For-10 Reverse Stock Split; Shares Fall 16% Pre-market
NASDAQ · 10/27 09:14
Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/27 08:53
More
Webull provides a variety of real-time ONCO stock news. You can receive the latest news about Onconetix through multiple platforms. This information may help you make smarter investment decisions.
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.